Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9HCG7

UPID:
GBA2_HUMAN

ALTERNATIVE NAMES:
Beta-glucocerebrosidase 2; Bile acid beta-glucosidase GBA2; Bile acid glucosyl transferase GBA2; Cholesterol glucosyltransferase GBA2; Cholesteryl-beta-glucosidase GBA2; Glucosylceramidase 2; Non-lysosomal cholesterol glycosyltransferase; Non-lysosomal galactosylceramidase; Non-lysosomal glycosylceramidase

ALTERNATIVE UPACC:
Q9HCG7; D3DRP2; Q5TCV6; Q96A51; Q96LY1; Q96SJ2; Q9H2L8

BACKGROUND:
Non-lysosomal glucosylceramidase, also referred to as Cholesterol glucosyltransferase GBA2, is integral in the transglucosylation of cholesterol and the metabolism of bile acids. Its ability to modify the solubility and biological properties of cholesterol underscores its significance in cellular dynamics and membrane properties.

THERAPEUTIC SIGNIFICANCE:
Given its association with Spastic paraplegia 46, a condition marked by progressive spastic paraplegia and cerebellar signs, the exploration of Non-lysosomal glucosylceramidase's role offers a promising avenue for the development of novel therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.